The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency

Isabella Quinti1*, Franco Locatelli2,3 and Rita Carsetti4,5

1 Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, 2 Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesù Children Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy, 3 Dipartimento Materno-Infantile e Scienze Urologiche, Sapienza University of Rome, Rome, Italy, 4 Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy, 5 Diagnostic Immunology Clinical Unit, Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy

CVID patients have an increased susceptibility to vaccine-preventable infections. The question on the potential benefits of immunization of CVID patients against SARS-CoV-2 offered the possibility to analyze the defective mechanisms of immune responses to a novel antigen. In CVID, as in immunocompetent subjects, the role of B and T cells is different between infected and vaccinated individuals. Upon vaccination, variable anti-Spike IgG responses have been found in different CVID cohorts. Immunization with two doses of mRNA vaccine did not generate Spike-specific classical memory B cells (MBCs) but atypical memory B cells (ATM) with low binding capacity to Spike protein. Spike-specific T-cells responses were also induced in CVID patients with a variable frequency, differently from specific T cells produced after multiple exposures to viral antigens following influenza virus immunization and infection. The immune response elicited by SARS-CoV-2 infection was enhanced by subsequent immunization underlying the need to immunize convalescent COVID-19 CVID patients after recovery. In particular, immunization after SARS-CoV-2 infection generated Spike-specific classical memory B cells (MBCs) with low binding capacity to Spike protein and Spike-specific antibodies in a high percentage of CVID patients. The search for a strategy to elicit an adequate immune response post-vaccination in CVID patients is necessary. Since reinfection with SARS-CoV-2 has been documented, at present SARS-CoV-2 positive CVID patients might benefit from new prevention strategy based on administration of anti-SARS-CoV-2 monoclonal antibodies.

Keywords: immunization, common variable immune deficiency, vaccine, antibodies, SARS-CoV-2

INTRODUCTION

The Committee of Experts on Primary Immunodeficiency of the International Union of Immunological Societies (IUIS) has included vaccination both as a diagnostic tool to assess the specific antibody response to protein and/or polysaccharide antigens and as a means of prevention (1).
The type and severity of the immunodeficiency determines the efficacy of vaccines, with varying levels of impairment, ranging from normal as in immunocompetent individuals, to incomplete or even absent. The degree of immunodeficiency and the specific defect in antibody production are variable in common variable immunodeficiency (CVID) (2) and each patient should be studied as unique in terms of cellular and humoral responses.

The decision to vaccinate a patient must include a risk and benefit assessment to ensure maximum protection and avoid adverse events. In addition, other factors, including the type of vaccine, the interval between administrations, and the time between gamma globulin administration and vaccination, must also be taken into account in defining an immunization strategy.

Here, we provide an updated perspective on the pathogenesis of CVID based on the studies performed on immune responses to vaccines with the aim to evaluate whether the immunization strategy for adult patients with CVID is effective. Studies on the potential benefits of immunization against SARS-CoV-2 offered the possibility to investigate the impaired pathogenic mechanisms of response to a novel antigen in patients with CVID.

SUSCEPTIBILITY TO VACCINE-PREVENTABLE INFECTIONS

CVID patients have an increased susceptibility to vaccine-preventable infections. Although the predominant infections are of bacterial origin, viral infections caused by rhinoviruses, parainfluenza, noroviruses, and herpesviruses, including varicella, herpes zoster (VZV), adenovirus, respiratory syncytial virus, that, in turn, play a role in driving an underlying inflammatory condition, are reported in CVID (3). SARS-CoV-2 infection also has been reported in CVID, since the beginning of the pandemic, with a low prevalence possibly due to the choice of most physicians to inform CVID patients early about safety measures, and to switch most patients to home therapy and remote assistance (4). Within SARS-CoV-2 infected patients with inborn errors of immunity, CVID patients represent the largest proportion since CVID is the most commonly diagnosed in IEI (5), have more comorbidities and older age (5). Moreover, CVID patients have an increased risk for prolonged infections and a low probability to clear viruses as it has been demonstrated for SARS-CoV-2 (6) as well as for the poliovirus, in particular when the number of peripheral blood B lymphocytes is low (7). Genetic differences contribute to individual variations in the immune response to pathogens and in the response to immunization. Pathogenic loss-of-function or gain-of-function heterozygous variants have been reported to be associated with CVID. However, their functional relevance for susceptibility to infection and response to vaccination remains to be clarified (8). Unfortunately, genetic causes of most CVID cases remain undefined, and the diagnosis is predominantly based on hypogammaglobulinemia with impairment of antibody response to vaccine or natural antigen and reduced memory B cells (MBCs) frequency.

Few data are available on genetic factors associated with the impaired SARS-CoV-2 response in CVID. A CVID patient with NF-kB2 loss-of-function variant who developed severe COVID-19 and a patient with TBK1 and TNFRSF13B mutations and an autoimmune inflammatory disease with lethal COVID-19 were reported (9, 10).

Table 1 illustrates immune alterations found in patients with CVID relevant for the impaired and variable response to vaccines (2). In the majority of patients, CVID is associated with defects in late stages of B cell development. In a group of CVID patients, plasma protein profiling identified a Th1-driven immune dysregulation, with increased plasma levels of IFN-γ and of proteins regulated by IFN-γ, NF-kB2 and NF-kB1 haploinsufficiency, or increased plasma levels of CXCL13 reflecting aberrant germinal center (GC) formation (12).

Aberrant germinal center reactions are also observed in previously healthy individuals affected by severe COVID-19. In these cases, the excessive reaction of the innate immune system with production of high concentrations of inflammatory cytokines disrupts the architecture of the germinal center thus preventing the response (13). The impaired germinal center reaction in COVID-19 leads to the generation of extral follicular responses and increase of atypical memory B cells (14).

Thus, the inability to perform the germinal center reaction genetically determined in CVID, is induced by the explosive innate immune reaction to SARS-CoV-2 in severe COVID-19.

VACCINATIONS IN CVID

As stated above, immunization can be used in patients with impaired and residual B-cell function to provide information on specific humoral immunity and to improve the outcomes related to vaccine-preventable disease. In CVID patients, vaccination is a tool to evaluate T-dependent and T-independent antibody residual function of B lymphocytes and it might be used to

Table 1 | Immune alterations relevant to impaired response to vaccines in CVID.

| Immune function                                      | Abnormality |
|-------------------------------------------------------|-------------|
| Immunoglobulin levels                                 | Reduced or absent |
| Bone marrow plasma cells                              | Depleted |
| Germinal Centre reaction                              | Impaired |
| Stimulation via Toll like receptors 7, 8, and 9 in B cells and/or plasmacytoid dendritic cells | Impaired |
| Switched memory B cells                               | Reduced or absent |
| Circulating CD4 T cells                               | Reduced |
| Naive CD4 T cells                                     | Reduced |
| Proliferation and activation of antigen-specific T cells | Reduced |
| CD40L expression                                     | Decreased |
| T follicular helper cells                             | Restricted |
| T-cell receptor repertoires                           | Reduced |
| IL-2, IL-10                                           | Increased |
| Thymic maturation                                    | Impaired |
| Monocyte/dendritic cell                               | Defective |
| Innate immune responses                               | Impaired |
| NK cells                                               | Reduced |

Bonilla et al., 2016 (11).
measure specific cellular immunity (15). Thus, vaccination has both a therapeutic and diagnostic role, but might be also useful to predict the prognosis (16). In fact, the inability to mount a response against the pneumococcal polysaccharide antigens or the inability to maintain the antibody response over time identified CVID patients with a severe immunological impairment. These patients have a great risk of comorbidities and poor prognosis. Alternative or complementary measurements of other polysaccharide responses have also been proposed, in an attempt to increase the diagnostic accuracy. For example, responses to the less frequently used Salmonella typhi pure polysaccharide vaccine (Typhim Vi) have been studied. In a multicenter study, Guevara-Hoyer et al. (17) demonstrated a lack of response in both Typhim Vi and pneumococcal immunization in a group of CVID patients, suggesting that the evaluation of the specific antibody response to Typhim Vi vaccine may add clinical value to the diagnosis of impaired anti-polysaccharide antibody production in CVID.

More detailed information is available on immune responses to vaccines against viral infections, including influenza and VZV vaccination.

Influenza vaccines provide protection by generating high-affinity antibodies against viral hemagglutinin. High-affinity antibodies are produced during the germinal center (GC) reaction through the interaction between T follicular helper cells and B cells. The response to vaccination can be measured by the increase of hemagglutination-inhibiting antibodies and specific T-cell responses, demonstrated by the presence of vaccine-induced CD4 T cells and cytokine production. CVID patients with switched MBCs (Euroclass smB+) (18) were shown to have T-cell cytokine responses to vaccines comparable to those of healthy controls, but the vaccine-specific antibody responses were found impaired in the group of patients with a more severe B-cell defect. As an alternative readout for the effective T-cell response to vaccination, it is possible to identify antigen-specific T cells by evaluating the upregulation of CD25 and CD134 (OX40) following in vitro re-stimulation with vaccine-derived peptides (19). VZV is the only human herpesvirus for which highly effective vaccines are available. The recent development of a liposome-based (HZ/su) subunit vaccine, which contains VZV, glycoprotein E and the adjuvant ASO1B, promises to change the perspectives for immunization against herpes zoster and its complications in adult CVID patients for whom a live-attenuated vaccine is not recommended (20). There is no data on the efficacy in primary antibody defects at present, but it is possible to hypothesize that, in response to the adjuvanted vaccine, specific T cells might be able to undergo activation and terminal differentiation, thus envisioning a potential benefit of subunit vaccination.

**INSIGHT ON SARS-CoV-2**

**The Adaptive Immune Responses**

Effective vaccines against SARS-CoV-2 are being administered worldwide with the aim of terminating the COVID-19 pandemics. As for all immunizations, the efficacy has been linked to the production of specific antibodies, which increase in response to all vaccines in use (21). It should be underlined that in the study population of the pre-approval studies, no patients with primary immune deficiencies were included (11). In immunocompetent subjects, the level of neutralizing antibodies is highly predictive of immune protection, and mRNA vaccination generated robust, multi-component humoral and cellular immune memory to SARS-CoV-2 for at least 6 months after mRNA vaccination (22). Moreover, boosting of pre-existing immunity with mRNA vaccines in SARS-CoV-2 recovered individuals increased antibody responses (23). While immunization shots and subsequent boosters raised antibody levels in immunocompetent subjects, it is unclear which CVID patients might reach protection, have a reduced infectious risk and disease severity. Data on immunogenicity of SARS-CoV-2 vaccine in patients with CVID are still limited. Since vaccination became available, Italian CVID patients, as well as CVID from other countries, were immunized mostly with mRNA COVID-19 vaccines. Four groups have recently reported immune responses to vaccines in patients with inborn errors of immunity, including CVID patients (24–27). In the study by Hagi et al., 70% of the adult patients with predominantly antibody deficiency developed specific humoral and T-cell responses after 2 doses of SARS-CoV-2 mRNA vaccine. About one third of CVID patients did not produce Spike-specific IgG, mainly including patients with low B cell number and reduced switched memory B cells. Two thirds of the patients had produced specific antibodies, in particular those belonging to the group with normal frequency of switched memory B cells (Euroclass smB+). The authors concluded that the GC reaction had a crucial role on protective antibody generation (24). Similarly, in the paper from Romano et al, 4 CVID patients developed neutralizing antibodies against SARS-CoV-2. The only patient who failed to have a substantial rise in post vaccination titers had a marked decrease in the frequency of circulating B cells (25). In a recent paper, a high percentage of fully immunized CVID patients developed anti-Spike IgG, at significantly lower levels than in the healthy control group (26). Our data (27) in CVID patients immunized with BNT162b2 SARS-CoV-2 mRNA vaccine contrasted with the high frequency of response reported in the cohorts illustrated above. We show that only 20% of CVID patients developed both anti-Spike IgG and IgA antibodies, and one patient responded with IgG only. Moreover, the level of antibodies in the few patients who produced specific IgG and IgA was significantly lower compared to vaccinated healthy donors. CVID patients who did not mount a detectable antibody response after immunization had lower frequency of switched memory B cells and lower serum IgA and IgM levels. In detail, 10% of those with low frequencies of switched memory B cells (<2%) showed a detectable humoral response. However, similarly to what observed in immunocompetent individuals, in some CVID patients who were previously infected with SARS-CoV-2, the IgG response was boosted by the subsequent immunization, showing that SARS-CoV-2 infection might effectively prime the immune response (28). Administration of BNT162b2
SARS-CoV-2 mRNA vaccine does not induce the production of specific SIgA in the mucosa of the respiratory tract in healthy individuals (29). It is therefore unlikely that vaccination may induce mucosal protection in CVID patients lacking SIgA. In order to protect SARS-CoV-2 CVID infected patient, passively infused SARS-CoV-2 monoclonal antibodies treatment was effective and well-tolerated in patients with Primary Antibody Defects (30).

The huge variation among the response rates reported (2) confirms that CVID includes a complex mixture of patients with different levels of immune impairment. In addition, as hypogammaglobulinemia is the hallmark of CVID, we still ignore whether the response to COVID vaccines will represent a durable or transient change of the B-cell repertoire in this category of patients. Whereas we expect that after the initial decline, antibody levels will reach a plateau in control subjects reflecting the establishment of the long-lived memory plasma cell pool, this may never happen in CVID and antibodies may rapidly become undetectable. For this reason, although antibody measurement, month after vaccination, is neither indicated nor useful for the majority of vaccinees, the change in the concentration of Spike specific antibodies may represent an important measure of the ability of CVID patients to prevent SARS-CoV-2 severe disease.

Additional information can be obtained by combining the analysis of the B cell phenotype with the detection of Spike and RBD-specific B cells. We concentrated our study on the B cell response, because, independently of whether in each single patient CVID is caused by defects of B, T or innate cells, the final outcome is the lack of antibody responses measurable by immunoglobulin concentration and B cell phenotyping. High specificity and affinity are the most important characteristics of protective MBCs, generated by the adaptive immune system in response to infection or vaccination (31). While the natural course of COVID-19 is primarily characterized by the function of the innate immune system, with a secondary involvement of T and B cells, SARS-CoV2 vaccines are designed to force the adaptive immune system to generate neutralizing antibodies and Spike antigen-specific memory B and T cells. Immunocompetent subjects responded to SARS-CoV-2 immunization by generating classical MBCs with high and low binding capacity for Spike and activated MBCs (32). Moreover, they also generated few ATM B cells with low binding capacity and plasmablasts with low and high binding capacity. In CVID, impaired differentiation of mature post-GC B-cells, with severely reduction of switched MBCs and plasmablast/plasma cells are the most consistent defects. Impaired maturation of B-cells might occur also at the pre-GC stage, leading to a strongly reduced number of B cells in the periphery (33). Upon vaccination, CVID patients did not generate classical and activated MBCs, but SARS-CoV-2 vaccination induced only ATM B cells with low binding capacity to Spike protein (27). It has been suggested that ATM B cells are short-lived activated cells, in the process of differentiating into plasma cells, ATM B cells may be produced by extra-follicular reactions or failure of the GC reactions (34). High affinity plasmablasts were not produced in CVID, while one third of the patients generated low affinity plasmablasts. None of the CVID patients generated memory B cells specific for the receptor binding domain (RBD) of SARS-CoV-2, indicating the incapability of CVID B-cells to undergo somatic mutation and affinity maturation in the GC indispensable for the production of neutralizing antibodies. This impairment, associated to the generation of atypical memory or classical memory B cells with low affinity for the Spike protein is the basis to hypothesize a sub-optimal and transient humoral immune response after vaccination in CVID patients.

Remarkably, CVID patient convalescents from COVID-19 generated classical Spike-specific MBCs after vaccination (28). Since natural infection responses are boosted by subsequent immunization, the comparison of immune responses generated by the vaccine and the infection will be important to shed light on the difference between an antigen-driven response and an infection-driven response.

The role of T cells in antiviral responses and formation of immunological memory in general is well-recognized. SARS-CoV-2-specific T cells have been identified in all T cell subsets, TCM, TEM, and TEMRA subsets in immunocompetent individuals. Indeed, several studies have demonstrated T cell memory and effector responses against a broad selection of epitopes from SARS-CoV-2, as well as cross-reactive responses in unexposed individuals (35). The majority of the immunocompetent subjects developed T-cell responses following immunization, with variable results observed only in aged individuals (36).

Spike-specific T-cells responses were induced in CVID patients with a variable frequency (37, 38), differently from T cells produced after multiple exposures to influenza viral antigen following immunization or infection. In a recent study, the vast majority of CVID patients had S1-specific T cells compared after two doses of immunization with mRNA vaccine (39). In our study (27), differently from influenza immunization, poor Spike-specific T-cell responses were generated by immunization. SARS-CoV-2 is a pathogen never encountered before, since SARS-CoV-2 Spike and the RBD domains are distinct from the Spike proteins of most members of the coronavirus family (40). Then, it is possible that the first antigenic stimulation was not sufficient to induce an early T-cell response in CVID.

**The Innate Immunity Responses**

Cells of the innate immune system play an essential role in early protection against infectious disease. To pathogens for which there is no preexisting immunity, the innate immune system is activated with the intent of limiting the infection while the adaptive immune response develops slowly and needs two weeks to generate the most specific and effective defensive tools: high affinity antibodies and memory B and T cells (41). After two years from the beginning of the pandemic, it remains unclear whether the condition of primary antibody deficiency is a predisposing or a protective factor for SARS-CoV-2 infection (42). Moreover, treatments for the immune deficiency status might also interfere with the disease progression and to the response to SARS-CoV-2 immunization. It should be
remembered here that patients with antibody deficiencies receive monthly immunoglobulin replacement therapy to substitute the lack of antibody production. The pool of immunoglobulin might include cross-reacting antibodies to SARS-CoV-2, and might act by modulating monocytes and macrophages activities, even when administered at replacement dosages (43). We suggested (44) that antibody deficiency patients might be protected from severe COVID-19 by loss of Interleukin-6 and by impaired toll-like receptor (TLR) pathway activation. TLR pathway activation is impaired in CVID, particularly activation by TLR7 and TLR9, involved in antiviral innate immune responses and in the cytokine storm leading to an exaggerated activation of lung residing immune cells (45). Thus, CVID patients might be partially protected against the dangerous macrophage hyperactivation resulting in cytokine storm. On the contrary, CVID patients with an underlying inflammatory chronic lung disease have a worse COVID-19 prognosis (46). CVID-associated immune dysregulation is a Th1-mediated inflammatory process driven by the IFN-γ pathway (47) and by a persistent activation on innate immunity (48), possibly due to the activation of IFN-γ:STAT1:BAFF axis leading to a dysregulated B cell responses (49). The interferon signature in CVID has been also linked to the expansion of circulating IFN-γ-producing innate lymphoid cells (50). Differently from COVID-19, the highly augmented IFN signaling and cytotoxic signature has not been detected after vaccination with the SARS-CoV-2 mRNA vaccines (51). In particular, the upregulation of gene signature associated with type I and type II IFN production was not observed in the immunized subjects, suggesting an adaptive immunity maturation in the absence of IFN signaling.

CONCLUSIONS

Despite the antibody deficiency, T-cell immunity is thought to be largely intact in many patients with CVID. For this reason, immunologists recommend routine administration of multiple vaccines with the exception of those containing attenuated viruses. Immunization of CVID patients against SARS-CoV-2 offered the possibility to analyze how defective mechanisms impact the immune response to a novel antigen. Discrepancy in the results published on antibody responses after SARS-CoV-2 immunization in CVID might be due to the heterogeneity of CVID populations enrolled or to different vaccination protocols. In CVID as well as in immunocompetent subjects, the nature of B- and T-cell responses differs dramatically between infected and vaccinated individuals, suggesting that inflammatory responses associated with infection influence the trajectory of the adaptive immune response. Moreover, the observation that the humoral immune response induced by natural infection was significantly enhanced by subsequent immunization underlines the need to immunize COVID-19 convalescent CVID patients after recovery. The search for a strategy to elicit an adequate protective immune response post-vaccination in CVID patients is necessary. This might include the changes of vaccination schedules, such as administration of multiple doses or to booster with heterologous vaccine preparation. In order to achieve protection of patients with immunodeficiency, new strategies may be necessary, such as the development of different types of vaccines, including those with inactivated viruses, high content of antigens, or with adjuvant. At present, we do not know whether CVID patients might require multiple doses or combinations of SARS-CoV-2 vaccines to obtain protection. Since reinfection with SARS-CoV-2 after vaccination or previous infection has been documented in CVID, at present SARS-CoV-2 positive CVID patients might benefit from the new preventing strategy based on administration of anti-SARS-CoV-2 monoclonal antibodies, and - in the next future - by the newly produced lots of gamma globulins for substitution therapy that will contain Spike-specific IgG.

The results obtained by the administration of mRNA vaccines against a virus never encountered by humans before has given us the possibility to study the different immune responses of the complex community of CVID patients and compare them to healthy controls. Thanks to the availability of new tools and methods, developed because of the COVID-19 pandemic, we are able not only to measure antibodies but also antigen-specific B and T cells. We should now combine the results obtained with the complete vaccine cycle and the booster dose, completed by a follow-up to measure the persistence of specific antibody and memory B cells. On the basis of this study it will be possible to distinguish the group of CVID patients who may benefit from vaccination and also pin-point the specific step of the immune response defective in each individual.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

IQ and RC elaborated data and wrote the manuscript. FL revised the article/supplementary material. Further inquiries can be directed to the corresponding author.

FUNDING

The work was funded by GSK project: Call for Prevention, Italian Ministry of Health COVID-2020-12371817 grant and grant “5 per mille, 2021” to RS. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

ACKNOWLEDGMENTS

We thank JMF for supporting our Research Center.
REFERENCES

1. Tangye SG, Al-Herz W, Boushaa A, Boushaa A, Chatila T, Cunningham-Rundles C, et al. Human Inborn Errors of Immunity: 2019 Update on the Classification From the International Union of Immunological Societies Expert Committee. J Clin Immunol (2020) 40:24–64. doi: 10.1007/s10875-019-00737-x

2. Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Moreta MT, et al. International Consensus Document (ICon): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract (2016) 4:38–59. doi: 10.1016/j.jaip.2015.07.025

3. Ponsford MJ, Price C, Farewell D, Greene G, Moore C, Perry M, et al. Increased Respiratory Viral Detection and Symptom Burden Among Patients With Primary Antibody Deficiency: Results From the BIPAD Study. J Allergy Clin Immunol Pract (2020) 9:735–44.e6. doi: 10.1016/j.jaip.2020.08.016

4. Pulvirenti F, Cinetto F, Milito C, Bonanni L, Pesce AM, Leodori G, et al. Health-Related Quality of Life in Common Variable Immunodeficiency Italian Patients Switched to Remote Assistance During the COVID-19 Pandemic. J Allergy Clin Immunol Pract (2020) 8:1894–9.e2. doi: 10.1016/j.jaip.2020.04.003

5. Milito C, Lougaris V, Giardino G, Punziano A, Vultaggio A, Carrabba M, et al. Clinical Outcome, Incidence, and SARS-CoV-2 Infection-Fatality Rates in Italian Patients With Inborn Errors of Immunity. J Allergy Clin Immunol Pract (2021) 9:2904–e2. doi: 10.1016/j.jaip.2021.04.017

6. Meys I, Bucigólo, Quinti I, Neven Bénédicte, Fischer A, Seoane E, et al. Coronavirus Disease 2019 in Patients With Inborn Errors of Immunity: An International Study. J Allergy Clin Immunol (2021) 147:520–31. doi: 10.1016/j.jaci.2020.09.010

7. Gram Grammatikos A, Donati M, Johnston SL, Gompels MM. Peripheral B Antibodies and Morbidity in COVID-19. J Allergy Clin Immunol Pract (2020) 8:2332–2340.e5. doi: 10.1016/j.jaip.2020.04.019

8. Harbecke R, Cohen JL, Otman MN. Herpes Zoster Vaccines. J Infect Dis (2021) 224:5429–42. doi: 10.1093/infdis/jiab388

9. Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol (2021) 12:714170. doi: 10.3389/fimmu.2021.714170

10. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA Vaccines Induce Durable Immunologic Memory to SARS-CoV-2 and Variants of Concern. Science (2021) 374(6572):eaem0829. doi: 10.1126/science.abm0829

11. Naaber P, Tserel L, Kangro K, Epp Seppb E, Jurjenson V, Adamsen A, et al. Dynamics of Antibody Response to BNT162b2 Vaccine After Six Months: A Longitudinal Prospective Study. Lancet Reg Health Eur (2021) 10:100208. doi: 10.1016/j.lanepe.2021.100208

12. Delmonte OM, Bergerson RE, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, et al. Antibody Responses to the SARS-CoV-2 Vaccine in Individuals With Various Inborn Errors of Immunity. J Allergy Clin Immunol (2021) 148:739–49. doi: 10.1016/j.jaci.2021.05.029

13. Romano C, Esposito S, Donnarumma G, Marrone A. Detection of Neutralizing Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients With Common Variable Immunodeficiency After Immunization With Messenger RNA Vaccines. Ann Allergy Asthma Immunol (2021) 127:499–501. doi: 10.1016/j.anai.2021.07.026

14. Hagen D, Freund T, Navon M, Halperin T, Adir D, Marom R, et al. Immunogenicity of Pfizer-BioNTech COVID-19 Vaccine in Patients With Inborn Errors of Immunity. J Allergy Clin Immunol (2021) 148:1192–7. doi: 10.1016/j.jaci.2021.08.016

15. Fernandez Salinas A, Piano Mortari E, Terreri S, Quintarelli C, Pulvirenti F, Di Cecca S, et al. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does Their Best. J Clin Immunol (2021) 41:1709–22. doi: 10.1007/s10875-021-01133-0

16. Pulvirenti F, Fernandez Salinas A, Milito C, Terreri S, Piano Mortari E, Quintarelli C, et al. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies. Cells (2021) 29:2915–30. doi: 10.3390/cells1012919

17. Quinti I, Piano Mortari E, Fernandez Salinas A, Milito C, Carsetti R, IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection. Front Cell Infect Microbiol (2021) 11:655896. doi: 10.3389/fcimb.2021.655896

18. Pulvirenti F, Milito C, Cinetto F, Salinas AF, Terreri S, Marra G, et al. SARS-CoV-2 Monoclonal Antibody Combination Therapy in Patients With COVID-19 and Primary Antibody Deficiency. J Infect Dis (2021) 554:1–5. doi: 10.1093/infdis/jiaa554

19. Tangye SG, Tarlinton DM. Memory B Cells: Effectors of Long-Lived Immune Responses. Eur J Immunol (2009) 39:2065–75. doi: 10.1002/eji.200939331

20. Pietro Mortari E, Russo C, Vinci MB, Terreri S, Fernandez Salinas A, Piccioni L, et al. Highly Specific Memory B Cells Generation After the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA. Cells (2021) 10:2541. doi: 10.3390/cells10102541

21. Del Pino-Molina L, Lopez-Granados E, Lecrevisse Q, Torres Canizales J, Perez-Andres M, Blanco E, et al. Dissection of the Pre-Germinal Center B-Cell Maturation Pathway in Common Variable Immunodeficiency Based on Standardized Flow Cytometric EuroFlow Tools. Front Immunol (2021) 12:603972. doi: 10.3389/fimmu.2020.603972

22. Bradlom AE, Batuguadza G, Bol S, Bunnik EM. Potential Functions of Atypical Memory B Cells in Plasmidium-Exposed Individuals. Int J Parasitol (2020) 50:1033–42. doi: 10.1016/j.ijpara.2020.08.003

23. Niessl J, Sekine T, Buggert M, T Cell Immunity to SARS-CoV-2. Semin Immunol (2021) 55:101505. doi: 10.1016/j.smim.2021.101505
36. Pegu A, O’Connell SE, Schmidt SD, O’Dell S, Talana CA, Lai L, et al. Durability of mRNA-1273 Vaccine-Induced Antibodies Against SARS-CoV-2 Variants. Sci (2021) 373:1372–7. doi: 10.1126/science.abj176.

37. Amenta R, Longhurst H, Steele R, Lehnert K, Leung E, Brooks AES, et al. Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19. J Allergy Clin Immunol Pract (2021) 9:3575–83. doi: 10.1016/j.jacip.2021.06.019.

38. Gupta S, Su H, Narsai T, Agrawal S. SARS-CoV-2-Associated T-Cell Immunity in Patients With Primary Immunodeficiency Disorders. J Immunol Res (2021) 2021:1305876. doi: 10.1155/2021/1305876.

39. Arroyo-Sánchez D, Cabrera-Marante O, Laguna-Goya R, Almendro-Vázquez P, Carretero O, Gil-Endo FJ, et al. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency. J Clin Immunol (2021), 1–13. doi: 10.1007/s10875-021-01174-5.

40. Steiner S, Sotzny F, Bauer S, Na IK, Schmuck-Henneresse M, Corman VM, et al. HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients. Front Immunol (2020) 11:607918. doi: 10.3389/fimmu.2020.607918.

41. Carsetti R, Zaffina S, Piano Mortari E, Terreri S, Corrente F, Capponi C, et al. Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases. Front Immunol (2020) 11:610300. doi: 10.3389/fimmu.2020.610300.

42. Babaha F, Rezaei N. Primary Immunodeficiency Diseases in COVID-19 Pandemic: A Predisposing or Protective Factor? Am J Med Sci (2020) 360:740–1. doi: 10.1016/j.amjms.2020.07.027.

43. Quinti I, Mitrevski M. Modulatory Effects of Antibody Replacement Therapy to Innate and Adaptive Immune Cells. Front Immunol (2017) 8:697. doi: 10.3389/fimmu.2017.00697.

44. Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A Possible Role for B Cells in COVID-19? Lesson From Patients With Agammaglobulinemia. J Allergy Clin Immunol (2020) 146:211–3.e4. doi: 10.1016/j.jaci.2020.04.013.

45. Yu JE, Knight AK, Radigan L, Marron TU, Zhang L, Sanchez-Ramon S, et al. Toll-Like Receptor 7 and 9 Defects in Common Variable Immunodeficiency. J Allergy Clin Immunol (2009) 124:349–56.e3563. doi: 10.1016/j.jaci.2009.05.019.

46. Milito C, Soccodato V, Aurora S, Pulvirenti F, Quinti I. COVID-19 in Complex Common Variable Immunodeficiency Patients Affected by Lung Diseases. Curr Opin Allergy Clin Immunol (2021) 21:535–44. doi: 10.1097/ACI.0000000000000789.

47. Hultberg J, Ernerudh J, Larsson M, Nådström-Augustinski J, Nyström S. Plasma Protein Profiling Reflects TLR1-Driven Immune Dysregulation in Common Variable Immunodeficiency. J Allergy Clin Immunol (2020) 146:417–28. doi: 10.1016/j.jaci.2020.01.046.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Quinti, Locatelli and Carsetti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.